Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Mato

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|November 4, 2019
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or ChemoimmunotherapyBruno Emond, Murali Sundaram, Hela Romdhani, et al.
The Oncologist|December 8, 2017
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of BiosimilarsJennifer R Brown, Florence Cymbalista, Jeff Sharman, et al.
Leukemia & Lymphoma|March 12, 2014
Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphomaAndré Goy, Mark Berger, Peggy Ford, et al.
Current Medical Research and Opinion|October 12, 2020
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemiaQing Huang, Bruno Emond, Marie-Hélène Lafeuille, et al.
JAMA Network Open|December 3, 2019
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic LeukemiaLindsey E Roeker, Maryam Sarraf Yazdy, Joanna Rhodes, et al.
Journal of Clinical Microbiology|June 14, 2013
Osteomyelitis of the patella caused by Legionella anisaMartha Cristina Sanchez, Rani Sebti, Patrice Hassoun, et al.
Haematologica|April 28, 2018
Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents eraAnthony Mato, Jordan Jahnke, Pengxiang Li, et al.
Medical Oncology (Northwood, London, England)|January 9, 2008
Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexaroteneCourtney D DiNardo, Bonnie Ky, Dan T Vogl, et al.
Hemasphere|August 18, 2020
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 PandemicDavide Rossi, Mazyar Shadman, Adalgisa Condoluci, et al.
British Journal of Haematology|February 11, 2019
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapiesJan A Burger, Paula Cramer, Paul M Barr, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma, Myeloma & Leukemia|November 4, 2019
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or ChemoimmunotherapyBruno Emond, Murali Sundaram, Hela Romdhani, et al.
The Oncologist|December 8, 2017
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of BiosimilarsJennifer R Brown, Florence Cymbalista, Jeff Sharman, et al.
Leukemia & Lymphoma|March 12, 2014
Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphomaAndré Goy, Mark Berger, Peggy Ford, et al.
Current Medical Research and Opinion|October 12, 2020
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemiaQing Huang, Bruno Emond, Marie-Hélène Lafeuille, et al.
JAMA Network Open|December 3, 2019
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic LeukemiaLindsey E Roeker, Maryam Sarraf Yazdy, Joanna Rhodes, et al.
Journal of Clinical Microbiology|June 14, 2013
Osteomyelitis of the patella caused by Legionella anisaMartha Cristina Sanchez, Rani Sebti, Patrice Hassoun, et al.
Haematologica|April 28, 2018
Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents eraAnthony Mato, Jordan Jahnke, Pengxiang Li, et al.
Medical Oncology (Northwood, London, England)|January 9, 2008
Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexaroteneCourtney D DiNardo, Bonnie Ky, Dan T Vogl, et al.
Hemasphere|August 18, 2020
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 PandemicDavide Rossi, Mazyar Shadman, Adalgisa Condoluci, et al.
British Journal of Haematology|February 11, 2019
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapiesJan A Burger, Paula Cramer, Paul M Barr, et al.
Pageof 7